fda aod9604 approval status AOD-9064 Fat-Metabolizing Peptide Fragment WHAT IT IS • Synthetic fragment of human growth hormone • Targets the fat-burning domain only • Does not significantly increase IGF-1 or affect glucose • Designed for You’re Injecting AOD-9604 WRONG! Doctor

What Patients Evaluating AOD 9604 Typically Report Timeline to first changes: Most published protocols note 4 to 6 weeks before body composition changes become measurable Areas of change: Visceral and subcutaneous fat reduction, with particular effect reported in the abdominal region in some subjects Energy and recovery: Some participants in clinical and investigational settings report improved energy and exercise recovery, though this is not a primary mechanism of the peptide What it is not: AOD 9604 does not cause rapid dramatic weight loss the way GLP-1 medications can in the first few months

Dinh Tran helps patients combat fatigue, mental fog, and a slowed metabolism with precisely targeted Vitamin B12 therapy

Genetic variants including GIPR rs1800437 , GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 influence how your body processes these medications, how much weight you lose, and how you tolerate side effects

While supplements are usually given as tablets, your doctor may recommend B12 injections, depending on your situation

Once youve dissolved the B12 in saline (which absorbs better than water and causes less pain), cover with aluminum foil

AOD 9604 injection , as a new type of anti-obesity polypeptide, acts directly on adipose tissue through subcutaneous injection